David Fernández-Quezada

Dr. David Fernández-Quezada

Neurociencias, Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara., Guadalajara, Jalisco, Mexico
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
DMDiana Emilia Martínez-Fernández
Diana Emilia Martínez-Fernández
David Fernández-QuezadaDavid Fernández-Quezada
David Fernández-Quezada
FCFidel Antonio Guadalupe Casillas-Muñoz
Fidel Antonio Guadalupe Casillas-Muñoz
FCFrancisco Josué Carrillo-Ballesteros
Francisco Josué Carrillo-Ballesteros
AOAna Maria Ortega-Prieto
Ana Maria Ortega-Prieto
Jose Angel Regla NavaJose Angel Regla Nava
Jose Angel Regla Nava
Monkeypox virus (MPXV) is an emerging zoonotic virus that belongs to the Orthopoxvirus genus and presents clinical symptoms similar to those of smallpox, such as fever and vesicular–pustular skin lesions. However, the differential diagnosis between smallpox and monkeypox is that smallpox does not cause lymphadenopathy but monkeypox generates swelling in the lymph nodes. Since the eradication of smallpox, MPXV has been identified as the most common Orthopoxvirus to cause human disease. Despite MPXV being endemic to certain regions of Africa, the current MPXV outbreak, which began in early 2022, has spread to numerous countries worldwide, raising global concern. As of the end of May 2023, over 87,545 cases and 141 deaths have been reported, with most cases identified in non-endemic countries, primarily due to human-to-human transmission. To better understand this emerging threat, this review presents an overview of key aspects of MPXV infection, including its animal reservoirs, modes of transmission, animal models, epidemiology, clinical and immunological features, diagnosis, treatments, vaccines, and prevention strategies. The material presented here provides a comprehensive understanding of MPXV as a disease, while emphasizing the significance and unique characteristics of the 2022 outbreak. This offers valuable information that can inform future research and aid in the development of effective interventions.

4 March 2025 in NeuroSci
Verified
Journal Article
Open access
PDF file
David Fernández-QuezadaDavid Fernández-Quezada
David Fernández-Quezada
DMDiana Emilia Martínez-Fernández
Diana Emilia Martínez-Fernández
IFIleana Fuentes
Ileana Fuentes
JGJoaquin Garcia-Estrada
Joaquin Garcia-Estrada
SLSonia Luquin
Sonia Luquin
Environmental noise has been repeatedly linked to negative effects on cognitive functioning among children and adolescents. This research sought to systematically assess studies investigating the relationship between noise exposure and cognitive outcomes in young individuals. Through a meta-analysis of eight primary studies published between 2001 and 2023, this study examined the effects of various noise types on cognitive performance across multiple domains in young populations. The findings reveal that noise exposure significantly impairs cognitive performance in children and adolescents, with a standardized mean difference (SMD) of –0.544 (95% CI: [−0.616, −0.472]), z = −14.85, p < 0.0001. These results underscore the profound impact of environmental noise on cognitive functioning in younger populations.

17 June 2025 in Frontiers in Digital Health
Verified
Journal Article
Open access
PDF file
AGAndrea P. Garzón-Partida
Andrea P. Garzón-Partida
CPCitlali B. Padilla-Gómez
Citlali B. Padilla-Gómez
DMDiana Emilia Martínez-Fernández
Diana Emilia Martínez-Fernández
JGJoaquín García-Estrada
Joaquín García-Estrada
SLSonia Luquin
Sonia Luquin
David Fernández-QuezadaDavid Fernández-Quezada
David Fernández-Quezada
Mood Disorders are a group of mental health conditions characterized by a disruption of the emotional state that affects the quality of life of the people living with them. Mental Disorders are difficult to diagnose and treat due to the complex processes involved and limitations of the healthcare system. Digital biomarkers have created accessible, long-term, non-invasive, and user-friendly alternatives for the diagnosis, treatment, and monitoring of these conditions. The use of everyday devices like smartphones and smartwatches and specialized tools like actigraphy, in conjunction with powerful statistical tools, artificial intelligence, and machine learning, represents a promising avenue for the implementation of personalized strategies to monitor and treat Mood Disorders, and potentially higher adherence to treatment. We conducted several studies that implement a variety of methodologies and tools to better understand Mood Disorders, using a patient-focused approach with the ultimate goal of identifying better strategies to improve their quality of life.

31 October 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
DMDiana Emilia Martínez-Fernández
Diana Emilia Martínez-Fernández
David Fernández-QuezadaDavid Fernández-Quezada
David Fernández-Quezada
AGAndrea P. Garzón-Partida
Andrea P. Garzón-Partida
IGIrene Guadalupe Aguilar Garcia
Irene Guadalupe Aguilar Garcia
JGJoaquin Garcia-Estrada
Joaquin Garcia-Estrada
SLSonia Luquin
Sonia Luquin
Substance use disorder (SUD) significantly impacts public health, economics, and legal systems worldwide. Eye Movement Desensitization and Reprocessing (EMDR) was initially developed in the late 1980s as a therapeutic approach for post-traumatic stress disorder (PTSD), using bilateral stimulation to integrate traumatic memories with calming physiological responses. However, the effectiveness of EMDR in treating SUD remains unclear. This study aims to conduct a systematic review and meta-analysis of the impact of EMDR therapy on craving reduction in individuals with SUD. The search was conducted using databases such as PubMed and Web of Science, focusing on studies that measured craving and employed EMDR interventions. Both random and fixed effects models were used to pool effect sizes, utilizing an R software meta-package (R-4.4.1). The study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The results indicated a significant reduction in cravings among patients undergoing EMDR therapy. Specifically, under the fixed effect model, the standardized mean difference (SMD) was −0.866 with a 95% confidence interval ranging from −1.121 to −0.611 (z = −6.66, p < 0.0001). These findings may demonstrate the significant efficacy of EMDR therapy in decreasing cravings in people with SUD.

27 June 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
AGAndrea P. Garzón-Partida
Andrea P. Garzón-Partida
KMKimberly Magaña-Plascencia
Kimberly Magaña-Plascencia
DMDiana Emilia Martínez-Fernández
Diana Emilia Martínez-Fernández
JGJoaquin Garcia-Estrada
Joaquin Garcia-Estrada
SLSonia Luquin
Sonia Luquin
David Fernández-QuezadaDavid Fernández-Quezada
David Fernández-Quezada
Background: Substance use disorder (SUD) involves excessive substance consumption and persistent reward-seeking behaviors, leading to serious physical, cognitive, and social consequences. This disorder is a global health crisis tied to increased mortality, unemployment, and reduced quality of life. Altered brain connectivity, circadian rhythms, and dopaminergic pathways contribute to sleep disorders, anxiety, and stress, which worsen SUD severity and relapse. Factors like trauma and socioeconomic disadvantages heighten risk. Digital health technologies, including wearables and machine learning, show promise for diagnosis, monitoring, and intervention, from relapse prediction to early detection of comorbidities. With high relapse rates and younger patient cases, these innovations could enhance the treatment outcomes of SUD. Objective: The objective of this study is to develop and validate a predictive model with machine learning for the duration of therapy and the rehabilitation or relapse in patients with SUD, using digital physiological measurements, psychological profiles, automatic facial emotion recognition, and the emotional state during craving. Methods: The study will be conducted with adult male patients with SUD at a rehabilitation center and control volunteers. Participants will undergo a self-reported demographic and psychological assessment, a clinician-administered craving and emotional reaction test, and will also be monitored using a smartwatch. SUD participants will be monitored for a total of 18 months (6 months during rehabilitation, an additional 12 months post discharge), and control participants for a total of 6 months. All participants will be reassessed at the sixth month of monitoring. The collected data will then be used to train models with a neural network, which will then be validated against other models and compared with other algorithms. Demographic, psychological, digital biomarkers, and craving profiles will be created, correlations will be analyzed, and they will be compared with controls to generate a digital phenotype of SUD. When the model achieves adequate validity (area under the curve of ≥0.80), a graphic user interface will then be designed for clinical use. Results: The study is supported by the Program for the Improvement of Working Conditions for Members of the SNII and SNCA (PROSNII U006EST), and APPAC-VII-CUCS-2025 for Article Publication Fees, from the University of Guadalajara. The research protocol was approved by the University of Guadalajara (reference CI-01225) in January 2025. Recruitment of patients with SUD and control participants will take place from January 2025 through January 2027. Conclusions: As shown in recent studies, accessible and affordable wearables, like commercial smartwatches, combined with psychological, demographic, and emotional state data, used with a machine learning predictive model, may be able to be used as tools to enhance SUD rehabilitation and prevent relapse. International Registered Report Identifier (IRRID): PRR1-10.2196/71374

Verified
Journal Article
Open access
PDF file
LPLiliana Rebolledo Pérez
Liliana Rebolledo Pérez
JHJorge Hernández-Bello
Jorge Hernández-Bello
AMAlicia Martínez-Ramos
Alicia Martínez-Ramos
RCRolando Castañeda
Rolando Castañeda
David Fernández-QuezadaDavid Fernández-Quezada
David Fernández-Quezada
IGIrene Guadalupe Aguilar Garcia
Irene Guadalupe Aguilar Garcia
Tau protein is essential for the structural stability of neurons, particularly through its role in microtubule assembly and axonal transport. However, when abnormally hyperphosphorylated or cleaved, Tau can aggregate into insoluble forms that disrupt neuronal function, contributing to the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD). Emerging evidence suggests that similar Tau-related alterations may occur in individuals with chronic exposure to psychoactive substances. This review compiles experimental, clinical, and postmortem findings that collectively indicate a substance-specific influence on Tau dynamics. Alcohol and opioids, for instance, promote Tau hyperphosphorylation and fragmentation through the activation of kinases such as GSK-3β and CDK5, as well as proteases like caspase-3, leading to neuroinflammation and microglial activation. Stimulants and dissociatives disrupt insulin signaling, increase oxidative stress, and impair endosomal trafficking, all of which can exacerbate Tau pathology. In contrast, cannabinoids and psychedelics may exert protective effects by modulating kinase activity, reducing inflammation, or enhancing neuroplasticity. Psychedelic compounds such as psilocybin and harmine have been demonstrated to decrease Tau phosphorylation and facilitate cognitive restoration in animal models. Although the molecular mechanisms differ across substances, Tau consistently emerges as a convergent target altered in substance-related cognitive disorders. Understanding these pathways may provide not only mechanistic insights into drug-induced neurotoxicity but also identify Tau as a valuable biomarker and potential therapeutic target for the prevention or treatment of cognitive decline associated with substance use.